



CURRICULUM VITAE

David Haim Sherr

39 Hastings Street, West Roxbury, Ma. 02132

Education:

1973 B.A. Brandeis University
Magna Cum Laude
Honors in Biology

1978 Ph.D. Cornell University
Major: Microbiology
Doctoral Thesis: Functional Development of B Lymphocytes
Sponsor: Gregory W. Siskind, M.D.
Minor: Microanatomy
Minor: Biochemistry

Postdoctoral Training:

1978-1980 Postdoctoral Fellow, Harvard Medical School, Department of Pathology,
Sponsors: Baruj Benacerraf, M.D., Nobel Laureate, Martin Dorf, Ph.D.

Academic Appointments:

1981-1982 Instructor, Harvard Medical School, Department of Pathology
1982-1987 Assistant Professor of Pathology, Harvard Medical School
1987-1993 Associate Professor of Pathology, Harvard Medical School
1993-present Professor of Environmental Health, Boston University School of Public Health
1993-present Professor of Pathology and Laboratory Medicine, Boston University School of
Medicine

Membership in University Research/Training Programs:

1993-present Member, Immunology Training Program
2009-2016 Director, Boston University Immunology Training Program
2000-2010 Member, Oncobiology Training Program
1995-present Member, Hematology/Oncology Training Program
1998-present Member, Amyloid Treatment and Research Program
2005-2011 Member, Women's Health Interdisciplinary Research Center (WHIRC)
2005-2007 Deputy Director, Center for Interdisciplinary Research in Environmental
Exposures and Health
2005-present Member, Boston University Cancer Center
2011-2014 Deputy Director, Boston University Superfund Research Program

David Sherr, Ph.D.

2014-present Director, Boston University Superfund Research Program
2014-present Member, Boston University Clinical Translation Scientific Institute (CTSI)

Membership in Advisory Committees:

1983-1988 Committee on Animal Use, Harvard Medical School
1989-1993 Committee on Animal Use, Institute for Circadian Physiology
1984-1993 Oliver Wendel Holmes Society for New Pathways in Medical Education, Harvard Medical School
1988-1993 Committee on Immunology, Harvard Medical School
1990 Study Section, Pathology B, NIH/PHS
1991 Study Section RFP #91-34, NIH/PHS
1991 Source Selection Committee, NIAID
1993 The Israel Science Foundation
1993-1994 Boston University School of Public Health Committee on Authorship
1996-2002 Publication Committee, Society for Experimental Biology and Medicine
1997 Boston University Anatomy Interim Chair Search Committee
1998-2005 Chair, Boston University School of Medicine, Immunology Training Program, Predoctoral Admissions Committee
2001-2004 Chair, Boston University School of Medicine, Oncobiology Training Program Predoctoral Admissions Committee
1998-2000 Committee of Publication, Society for Experimental Biology and Medicine
1999-2000 Chair, Department of Environmental Health, Faculty Search Committee
1999-2005 Advisory Committee to the Dean on Construction and Use of Genetically Altered Laboratory Animals
2000-2001 Ad hoc. Study Section, National Institute of Neurological Disorders and Stroke
2001 Grant Reviewer, Hudson River Foundation
2001-2003 Boston University Institutional Animal Care and Use Committee
2001-present Appointments and Promotions Committee, Boston University School of Public Health
2001 Study Section NIH/NINDS, RFA 2000-2001 Toxicogenomics Research Study Section RFA ES 01-002, NIH/PHS
2002-2003 Department of Environmental Health, Chair Search Committee
2004 Sub co-chair, ES1 LWJ-B-AR study section, NIH/PHS
2005-2008 Laboratory Animal Space Oversight Committee, Boston University Medical Center
2005-2006 Dean's Committee for Core Implementation and Oversight, Boston University Medical Center
2006-2008 Co-Director, Boston University Center for Interdisciplinary Research in Environmental Exposures and Environmental Health (CIREEH)
2007-present Reviewer, Boston University Cancer Research Center, American Cancer Society Grant Award
2007-2010 Boston University School of Medicine Mouse User Committee
2008-present Member, 2008 University of Texas Medical Branch NIEHS Center External Advisory Committee
2008 Reviewer, Walter Rosenblith New Investigator Award

David Sherr, Ph.D.

2008-2010 Member, Internal Research Advisory Committee, Boston Veteran's Administration Environmental Hazards Center
2008-2011 Investigator Boston University School of Medicine Conflict of Interest Committee
2008 NIH/NIEHS/P42 study section (Superfund)
2007-present Art beCAUSE Breast Cancer Foundation Medical Review Board
2009-2014 Executive Board, Women's Health and Interdisciplinary Research Center (WHIRC)
2009-2010 Department of Pathology, Faculty Search Committee
2009-2014 Department of Microbiology, Faculty Search Committee
2009-2010 Department of Environmental Health, Faculty Search Committee
2010 NIEHS Autoimmunity and the Environment Workshop (Mechanisms Panel)
2010-2011 Investigator Boston University School of Medicine Conflict of Interest Committee
2010-present Member, Boston University Cancer Center Executive Committee
2010-present Member, BU Graduate Medical Sciences Steering Committee
2010 Reviewer, Congressionally Directed Medical Research Programs (CDMRP)
2011 NIH/NIEHS S Study Section, Deep Water Horizon Consortia U19 ZES1 LWJ-J
2011 NIH Study Section mail reviewer, Tumor Microenvironment Study Section
2011-present Boston University Medical Campus High Throughput Screening Facility Internal Advisory Committee
2011-present Superfund Research Program Internal Advisory Committee
2012 Cancer Research Initiative - Internal Advisory Board Meeting
2012 NIH/NIEHS Study Section, P42 ZES1 LWJ-D (Superfund)
2013-2015 NIH Study Section, ZRG1 SIEE-C(01), Systemic Injury by Environmental Exposure
2015 Vice Chair, BU Division of Graduate Medical Sciences, Minimal Technical Competency Committee (to establish guidelines for accepting handicapped graduate students)
2015 Member, External Advisory Board, Brown University Superfund Research Program P42.
2015 Member, Internal Advisory Committee, Immunobiology of Trauma T32
2015 Chair, NIH/NIEHS Study Section ZRG1 DKUS (C950)
2016 NIH Study Section, Systemic Injury by Environmental Exposure
2016 Scientific Organizing Committee, AHR Conference 2016, U. Rochester

Directorships:

2006-2011 Director, Boston University Medical Campus Flow Cytometry Core Facility
2009-2016 Director, Boston University Immunology Training Program
2012-2014 Deputy Director, Boston University Superfund Research Program
2014-present Director, Boston University Superfund Research Program

Journal Reviewer for:

1986-present The Journal of Immunology
1986-present Immunological Investigations
1985-present The Journal of Clinical Investigation

David Sherr, Ph.D.

1988-present Cellular Immunology
1994 The Journal of Toxicology and Environmental Health
1994 Biochimica et Biophysica Acta
1995-present Toxicology and Applied Pharmacology
1996-present Immunology Letters
2000-present Toxicological Sciences
2002 Canadian Journal of Chemistry
2004 Environmental Toxicology
2004 Journal of Electrostatics
2005-present Toxicological Letters
2005-2013 Environmental Research
2005-present Molecular Pharmacology
2004-present Environmental Health Journal
2005-present Molecular and Cellular Biochemistry
2007-present Breast Cancer Research
2009 Cellular and Molecular Life Sciences
2009 Cancer Chemotherapy and Pharmacology
2011 Arteriosclerosis, Thrombosis, and Vascular Biology
2011-present Journal of Cellular Biochemistry
2012-present PLoS ONE
2015 BMC Immunology
2016 Stem Cell

Journal Review Board:

1991-2001 Society for Experimental Biology and Medicine

Society Memberships:

American Association of Immunologists
Society for Clinical and Translational Science
Society for Experimental Biology and Medicine
American Association for the Advancement of Science
Society of Toxicology

Invited Speaker (1998-present):

1998 New England Membrane Enzyme Group; Putman, Vt. “The role of the aryl hydrocarbon receptor (AhR) in breast cancer”
1999 New England Membrane Enzyme Group; Woods Hole Massachusetts; “The AhR and NF- κ B; It’s a matter of life and death”
2001 University of Rochester; Rochester, N.Y.; “Mechanisms of PAH-induced pre-B cell apoptosis”
2001 Massachusetts Department of Public Health Breast Cancer Program, Boston, MA. “The relationship between environmental chemicals and breast cancer.”
2002 Department of Defense Breast Cancer Research Program, Era of Hope; Orlando, Fla. “The aryl hydrocarbon (dioxin) receptor and AhR-regulated CYP1B1 as targets for cancer immunotherapy”

- 2003 Department of Genetics and Genomics, Boston University Medical Center. “The aryl hydrocarbon receptor: What is it good for?”
- 2004 Alliance for a Healthy Tomorrow seminar; Northeastern University, Boston “Toxicology; Past, Present, and Future”
- 2004 University of Virginia, Charlottesville, Va. “Environmental Chemical-induced B Cell Apoptosis”
- 2004 Virginia Commonwealth University, Richmond, Va. “PAH-induced B cell apoptosis”
- 2004 University of Massachusetts, Boston, MA. “The Aryl Hydrocarbon Receptor (AhR): An Environmental Pollutant-Activated Transcription Factor, Influences Cell Growth and Death”
- 2005 Charles River Laboratories, Symposium on Novel Approaches to Oncology Research. Waltham, MA. “Targeting the AhR, an environmental carcinogen receptor, and proteins it regulates for tumor immunotherapy”
- 2005 University of Dusseldorf, Conference on Dioxins and the Immune System. Dusseldorf, Germany. “The role of the AhR in mammary tumorigenesis”
- 2005 Boston University Women’s Health Interdisciplinary Research Center. Emerging Issues in Women’s Health. “The Role of the aryl hydrocarbon receptor in mammary tumorigenesis”
- 2006 Texas A & M University, College Station, TX. “The AhR: What is it good for?”
- 2006 Pulmonary Division, Boston University School of Medicine “The AhR in epithelial cell function”
- 2007 Department of Medicine, Boston University School of Medicine. “The role of the aryl hydrocarbon receptor in mammary epithelial cell growth and invasiveness”
- 2007 Distinguished Scholars in Toxicology Spring Seminar; Center for Integrative Toxicology, Michigan State University. “The role of the AhR, and environmental chemical receptor, in mammary growth and invasion”
- 2007 Society of Toxicology Symposium. Charlotte, North Carolina. “AhR Transcriptional Regulation and Its Impact on Mammary Tumor Behavior”
- 2008 University of Texas, Galveston. “The role of the AhR, an environmental carcinogen receptor, in breast cancer progression.”
- 2009 University of Kentucky. “The AhR and mammary tumorigenesis: It’s not nice to fool mother nature”
- 2009 University of New England Medical School “The AhR and breast cancer”
- 2010 McGill University, Montreal, Canada “The AhR, an environmental chemical receptor, controls mammary gland tumorigenesis”
- 2010 New England Membrane Enzyme Group, Woods Hole Oceanographic Institution. “Multiple cellular and molecular mechanisms through which environmental chemicals compromise B lymphocyte development”
- 2011 Workshop on Immunotoxicity in Humans. National University Hospital, Copenhagen, Denmark “The Ah receptor and assessment of AhR-inducing activity in human serum”
- 2011 Art BeCAUSE Breast Cancer Foundation, Boston, MA. Keynote speaker: “Breast cancer prevention: Scientific challenges and opportunities”.
- 2012 National Institute of Environmental Health Sciences Symposium, American Association of Immunologists, Boston, MA. “Environmental Chemicals as Probes of Immune System Development”

David Sherr, Ph.D.

- 2012 Department of Cell and Molecular Biology, Boston University School of Medicine “Regulation of aryl hydrocarbon receptor activity during tumorigenesis”
- 2012 Clinical and Translational Science Institute, Boston University “Targeting the AhR in triple negative breast cancer”.
- 2012 Hariri Institute Workshop, Boston University “Computational Biology and the Promise of Unraveling the Role of the Aryl Hydrocarbon Receptor in Cancer”.
- 2012 Evan’s Foundation Symposium “Computational Genomic Models”
- 2014 SOT Symposium. Phoenix, Az. “The AhR controls breast cancer stem cell development and function”.
- 2014 Society of Toxicology, Lone Star Regional Chapter, Austin, Tx. Keynote address: “The role of the AhR in environmental chemical receptor, in cancer stem cell biology”.
- 2014 The Collaborative on Health and the Environment, Partnership teleconference: “The health effects of PCBs”. Boston, MA/Bolinas, Calif.
- 2015 Evans Foundation Symposium, “Computational then cancer biology”, Boston, MA
- 2015 Pennsylvania State University. “The role of the aryl hydrocarbon receptor in cancer, blood cell specification, and thrombosis”, University Park, Pennsylvania
- 2015 Boston University Cancer Seminar Series: The Aryl Hydrocarbon Receptor, an Environmental Chemical Sensor, and Cancer. All Cancers? Boston, MA
- 2015 Sterling Drug Distinguished Lecturer, Boston University School of Medicine, Pharmacology Department: “Why evolution saved the AHR”, Boston, MA.
- 2015 EPA Region 1. “The Boston University Superfund Research Program”, Boston, MA.
- 2016 Harvard School of Public Health: “The role of an environmental chemical receptor, the AHR, in cancer stem cell production and invasion”, Boston, MA
- 2016 Boston University Research on Tap: “The method of functional modules for repositioning drugs for breast cancer therapy”, Boston, MA.
- 2016 Boston University Research on Tap: “The computational genomics models of environmental chemical carcinogenicity ARC”, Boston, MA.
- 2016 Art BeCAUSE Breast Cancer Foundation at Casner and Edwards, John Hancock Insurance: “Breast cancer and the environment consortium”, Boston, MA.
- 2016 International AHR Conference 2016, “AHR Control of Oral Squamous Cell Carcinoma Migration and Tumorigenesis. University of Rochester School of Medicine, Rochester, NY.
- 2016 International AHR Conference 2016, “Conference Summary”. University of Rochester School of Medicine, Rochester, NY.
- 2016 International Congress of Toxicology: “Identification and use of therapeutic AhR modulators”, Merida, Mexico

Teaching:

- 1978-1993 Ongoing Seminar Series, Pathology Department
Immunology Course, Harvard Medical School
- 1982-1984 Harvard Medical School Immunogenetics Course
- 1982-1993 Speaker, Research in Progress Seminar Series
- 1986-1993 Reviewer, Practical laboratories in Immunology, Pathology, and Microbiology for Identity and Defense course, Harvard Medical School
- 1986-1993 Student evaluator for Human Biology II, Harvard Medical School
- 1987-1993 Lecturer, Identity and Defense course, Harvard Medical School

David Sherr, Ph.D.

1988-1993 Graduate Student Journal Club, Harvard Medical School
1989-1993 Lecturer, Basic Immunology, Harvard Medical School
1992-1993 Director/Lecturer, Basic Immunology Course, Immunogen, Inc.
1993-present Lecturer, Comprehensive Immunology, Boston University School of Medicine
1993-1999 Course Co-Director/Toxicology, Boston University School of Public Health
1998-present Lecturer, Toxicology, Boston University School of Public Health
1993-2002 Lecturer, Special Topics in Pathology, Boston University School of Medicine
1993 Lecturer, Immunology, Boston University Citylab
1994-1995 Director, Immunology Training Program Seminar Series
1998-present Lecturer, Intermediate Toxicology, Boston University School of Medicine
1995-2001 Lecturer, Basic Pathology, Boston University School of Medicine
1999 Mentor, Boston Area Health Education Center
2000-present Lecturer, Cancer Biology, Boston University School of Medicine
2002-2012 Co-director, Molecular Biology and Public Health, Boston University School of Public Health
2010 Lecturer, BU School of Management (HM801), Bench to bedside; Translating Biomedical Innovation from the Laboratory
2010-present Director, Molecular Biology and Public Health, Boston University School Public Health

Teaching Awards:

1998 Excellence in Teaching Award, Boston University School of Public Health (Principles in Toxicology)
2005 Excellence in Teaching Award, Boston University School of Public Health (Molecular Biology and Public Health)
2006 Nominated for Boston University School of Medicine Educator of the Year Award (Cancer Biology Course)
2007 Nominated for Boston University School of Medicine Educator of the Year Award (Cancer Biology Course)
2008 Nominated for Boston University School of Medicine Educator of the Year Award (Environmental Health Course)
2009 Nominated for Boston University School of Medicine Educator of the Year Award
2011 Excellence in Teaching Award, Boston University School of Public Health (Molecular Biology and Public Health)

Sponsorship of Post Doctoral Fellows:

1985-1987 Perry Hausman, Ph.D.
1986-1990 Richard O'Harra, Ph.D.
1988-1989 Yutaka Kawano, M.D.
1989-1990 Masahiko Itoh, M.D.
1990-1993 Fumihiko Hinoshita, M.D.
1988-1993 Janet A. Hardin, Ph.D.
1993-2000 Richard Near, Ph.D.
1993-1994 Koichi Yamaguchi, M.D.
1995-1998 Raymond Matulka, Ph.D.

David Sherr, Ph.D.

1995-2001 Shafat Quadri, Ph.D.
1999-2004 Jennifer Schlezinger, Ph.D.
1999-2000 Koren Mann, Ph.D.
2000-2002 Brenda Jensen, Ph.D.
2001-2007 Xinhai Yang, Ph.D.
2001-2004 Tessa J. Murray, Ph.D.
2002-2005 Tahamtan Ahmadi, M.D.
2005 Lenka Allan, Ph.D.
2004-2006 Yvonne Efebera, M.D.
2006-2008 Zhao Lu, M.D.
2008-2010 Amanda Flies, Ph.D.
2009-2010 Sandra Solomon Rolfe, Ph.D.
2012-2013 Ashley Parks, Ph.D.
2014-present Zhongyan Wang
2015-2016 Elizabeth Stanford, Ph.D.

Sponsorship of Pre-Doctoral Graduate Students:

1995-1999 Koren Mann (EPA Star Award; Russek Award Winner)
1995-2001 Anthony Trombino
1996-2003 Heui-Young Ryu
1999-2001 Maria Rodriguez
2001-2006 Lenka Pospisil-Allan (Russek Award Winner)
2001-2008 Amanda Flies (2006 Boston University Science and Engineering Day Award for Technology Development)
2003-2008 Jessica Emberley (2005 Boston University Science and Engineering Day, School of Public Health, Award for Outstanding Research Presentation; 2007 Boston University Science and Engineering Day, School of Medicine Award for Outstanding Research Presentation, 2004-2007 EPA STAR Award, 2007 Russek Award Honorable Mention)
2003-2009 Sandra Solomon Rolfe (Boston University Graduate School of Medical Sciences 2009 Commencement student speaker)
2005-2012 Supraja Narasimhan (Carcinogenesis Specialty Section, Society of Toxicology Best Abstract Award, 2008; Art beCAUSE Breast Cancer Foundation grant recipient; 2008 Boston University. Graduate Medical Sciences Research Fellowship Award)
2009-2012 Ashley Parks
2010-2016 Olga Novikov (M.D./Ph.D.), Dean's Award, Boston University School of Public Health, 2015
2012-2015 Elizabeth Stanford (Levinsky fellowship, Department of Medicine, Boston University School of Medicine 2011-2013)(Art BeCAUSE Breast Cancer Foundation "Seed The Scientist" Awardee, 2012-2014)(New England Society of Toxicology Travel Award, 1rst Prize)(Russek Research Day Competition, First runner up)(BU Graduate Medical Sciences Student Commencement Speaker)

Sponsorship of Masters Students:

1999-2001 Todd Jenkins

David Sherr, Ph.D.

2005-2006 Pamela Bernard
2008-2009 Olga Novikov
2011-2013 Jessalyn Ubellacker

Sponsorship of Undergraduate Students:

2008 Prianca Joshi
2009 Esneider Gomez
2010 Vaughn Eyvazian
2011 Andrew Schiff
2015 Bonnie Campbell
2016 Nirisha Commodore

Sponsorship of CityLab, Bioscience Academy Students:

2005-2006 Sandra Bustamante Lopez
2012-2013 Haider Alhemayri

Ph.D./D.Sc. Thesis Advisory Committees:

1993-1997 Julia Wang
1994-1997 Mika Sovak (Second reader/Thesis committee chair)
1994-1997 Stephanie Schauer
1996-1999 Koren Mann (Thesis advisor)
1996-2000 Laurie Hafer
1998-2000 Dong Kim
1998-2000 Maria Rodriguez (Thesis advisor)
1997-2000 Anthony Trombino (Thesis advisor)
1997-2004 Heui-Young Ryu (Thesis advisor)
1997-2001 Michelle Youd
1999-2002 Xuemei Zhong (Second reader/Thesis committee chair)
1999-2002 Elizabeth Ledbetter
1999-2001 Jian Shen
1999-2004 Elena Sabbaugh
1999-2002 Stephan Murray
2000-2002 Brent Williams
2000-2003 Michael Mansour
2001-2005 William Hastings
2001-2003 Sheng Xiao (Second reader/Thesis committee chair)
2002-2004 Derek V. Chan (Second reader/Thesis committee chair)
2002-2008 Amanda Flies (Thesis advisor)
2002-2005 Lenka Pospisil-Allan (Thesis advisor)
2003-2008 Jessica Emberley (Thesis advisor)
2003-2009 Sandra Solomon (Thesis advisor)
2003-2008 Deepa Subramanian (Second reader/Thesis committee chair)
2005-2011 Supraja Narasimhan (Thesis advisor)
2005-2007 Nicholas Currier (Second reader/Thesis Committee Chair)
2005-2006 Gerassimos Bastas
2005-2009 Nichol Holodic

David Sherr, Ph.D.

2005-2008	Melisa Uccellini
2006-2011	Allison Mangini (Second Reader/Thesis Committee Chair)
2007-2009	John Meyers (Second reader)
2008-2009	Lyndsey Emery
2008-2010	Daniel Green
2008-2009	Maura Hobson
2008-2011	Nathanial Green
2008-2010	Beth Hovey
2009-2012	Adam Gower
2009-2011	Amelia Haas (Second reader)
2009-2012	Ashley Parks (Thesis Advisor)
2010-2016	Olga Novikov (Thesis Advisor)
2010-2012	Karla Boyd
2011	Lee Albacker (Harvard Medical School)
2011-2012	Cassandra Browning (CRC, Bioengineering)(Second reader)
2011-2014	Dolly Thomas (second reader)
2011-2014	Sarah Rozelle
2012-2015	Elizabeth Stanford (Thesis Advisor)
2012-205	Daniel Gusenleitner
2012-present	Theresa Colvin
2013-present	Caitlin Miller
2013-present	Jessica Allen
2013-present	Jacquelyn Sikora
2014-present	Carly Garrison (Thesis Committee Chair)
2014-present	Hsiao-Rong Chen (Charles River Campus)(First reader)
2014-present	Amy Li
2014-present	Jessica Ritter
2015-present	Traci Bethea
2015-present	Elizabeth Moses (Thesis Committee Chair)
2015	Youjin Lee (Harvard Medical School, Dissertation Defense Committee)
2015-present	Brendan Smith (Second reader)
2015-present	Hsiao-Rong Chen (First reader)

Qualifying exam committees:

2015 Kathryn Crawford
2016 Lariah Edwards

Master's Advisory Committee:

2004-2005 Joanne Lundgren (Second Reader)
2015 Susan Kim (First Reader)

Past Research Support:

1981-1982 Cancer Research Institute
1982-1983 Medical Foundation
1982-1984 March of Dimes, Birth Defects

David Sherr, Ph.D.

1984-1986 March of Dimes, Birth Defects
1985-1986 American Cancer Society
1986-1988 March of Dimes, Birth Defects
1987-1992 Public Health Service, RO-1
1988-1990 March of Dimes, Birth Defects
1988 Wellington Foundation
1989-1991 Genetics Institute
1989-1991 American Cancer Society
1991-1992 Pardee Foundation
1991-1992 M.I.T. Center for Environmental Health Sciences
1992-1993 Wellington Foundation
1992-1993 Proctor Fund
1992-1994 Public Health Service, Shannon Award
1993-1994 American Institute for Cancer Research
1993-1997 Public Health Service R0-1
1994-1997 Intergovernmental Group of the United Nations
1994-1999 Veterans Administration
1995-1999 Department of Defense, Breast Cancer Initiative
1995 Fuller Foundation
1998-2005 Public Health Service RO-1 (The role of the AhR in ovariar development)
2001-2002 US Department of Defense Breast Cancer Initiative, Concept Award
2001-2005 Public Health Service RO-1 subcontract (Effects of perinatal endocrine disrupters in children)
2000-2003 Gerry Foundation
2002-2007 Public Health Service PO-1 (A novel approach to primary amyloid immunotherapy)
2003-2007 Public Health Service RO-1 subcontract (Children's vulnerability to environmental immunotoxicant exposure)
2006-2008 Avon Breast Cancer Foundation (The aryl hydrocarbon receptor in translational breast cancer research)
2008-2009 Clinical and Translational Science Award (CTSA)(Preclinical studies to develop a polyvalent vaccine for AL amyloidosis and related B lymphocyte cancers)
2008-2009 Center for Integration of Medicine and Innovative Technology (CIMIT) (Transdermal injection of nanoparticles via electrospray and pulsed- field assist)
1993-2010 PI, Public Health Service RO1 (How Environmental Chemicals Suppress Immunity)
2009-2011 Co-investigator, Public Health Service R21 (Environmental Phthalate- and PPAR γ -mediated Toxicity in the Developing Immune System")
1995-2011 Associate Director, Co-investigator Superfund Basic Research Program, Public Health Service
2010-2011 Healthcare Ignition Award (Selective aryl hydrocarbon receptor (AhR) modifiers as novel breast cancer therapeutics)
2008-2013 Co-investigator, Public Health Service RO1 (Roles of NF- κ B/Rel in the pathogenesis of breast cancer)
2012-2013 PI, Coulter Award (AhR modulator-loaded poly(glycerol-co- ϵ -caprolactone) film validation)

David Sherr, Ph.D.

- 2012-2014 PI, Mary Kay Breast Cancer Foundation (A novel, AhR-targeted therapeutic for triple negative and chemo-resistant breast cancers)
- 2012-2014 Sponsor, Art beCAUSE Breast Cancer Foundation Seed the Scientist Awardee (Elizabeth Stanford)
- 2001-2014 PI, Project 1, Public Health Service PO-1, PI project 1 (The role of the AhR in breast cancer)
- 2013-2015 Co-PI, Public Health Service P42 supplement (A platform for predicting xenobiotic toxicity and carcinogenicity)
- 2014-2016 Sponsor, EPA STAR Awardee (Elizabeth Stanford)
- 2010-2015 Co-investigator, Public Health Service RO1 (Lysyl oxidase propeptide: Breast cancer inhibitor)

Active Research Support:

- 2009-2016 PI, Public Health Service T32 (NIAID) (Research Program in Immunology)
- 2011-2016 Co-Investigator, Public Health Service RO1 (Epidemiology of immunotoxicant exposure in children)
- 2012-2016 Co-PI, BU Area of Research Concentration (ARC) (Computational Models of Environmental & Chemical Carcinogenicity)
- 2012-2017 PI, Public Health Service P42 (Superfund Research Program at Boston University)
- 2013-2016 Co-Investigator, Public Health Service RO1 (Airway epithelium profiling for evaluation of e-cigarettes & tobacco products)
- 2014-2017 Co-Investigator, VICTOR award. (Stress Granules and the Biology of TDP-43)
- 2014-2016 PI, Avon Breast Cancer Foundation Award (The role of an environmental chemical receptor in development and propagation of breast cancer stem cells)
- 2014-2017 PI, Art beCAUSE Breast Cancer Foundation Consortium (Environmental chemicals and prevention of human breast cancer/Art BeCAUSE Breast Cancer Consortium)
- 2016-2021 Co-PI, Public Health Service RO1 (NIEHS) (Defining the role of the AHR in blood cell specification)
- 2015-2016 LINCS Administrative Supplement, NIEHS. (High-throughput transcriptomic models for the fast and accurate prediction of chemical carcinogenicity and toxicity)

Patents :

#00980436.0-2110-US0031513: Cancer immunotherapy and diagnosis using cytochrome P450 1B1.

Provisional Patent filed 7/7/10: Multiple myeloma and AL amyloid immunotherapy targeting immunoglobulin light chains and uses thereof. USPTO #12/102691

National Patent filed 1/27/13: Aryl hydrocarbon receptor modifiers as novel cancer therapeutics. USPTO #61368042

Provisional Patent filed: 5/12: Production of red blood cells and platelets from pluripotent stem cells. USPTO #61683246

David Sherr, Ph.D.

Provisonal Patent filed 8/16: A method for repurposing approved drugs. USPTO #62343359

Research Interests:

1. The aryl hydrocarbon receptor (AHR), environmental carcinogens, and breast cancer
2. Cancer prevention and therapy
3. Intracellular signaling induced by aromatic hydrocarbons and environmental AHR ligands

Bibliography:

Peer Reviewed Journals and Books only:

1. **Sherr DH**, Siskind GW. Studies on the control of antibody synthesis. XI. Effect of antigen on the localization of cells secreting different avidity antibodies, *Proc Soc Exp Biol Med.* 1977; 155:203. PMID: 68477
2. **Sherr DH**, Szewczuk, MR, Siskind GW. Ontogeny of B lymphocyte function. IV. Kinetics of maturation of B lymphocytes from fetal and neonatal mice when transferred into adult irradiated hosts. *J Immunol.* 1977; 199:1674. PMID: 334968
3. **Sherr DH**, Szewczuk MR, Siskind GW. Ontogeny of B lymphocyte function. V. Thymus cell involvement in the functional maturation of B lymphocytes from fetal mice transferred into adult irradiated hosts. *J Exp Med.* 1978; 147:196. PMC2184108
4. Szewczuk MR, **Sherr DH**, Siskind GW. Ontogeny of B lymphocyte function. VI. Ontogeny of thymus cell capacity to facilitate the functional maturation of B lymphocytes. *Eur J Immunol.* 1978; 8:370. PMID: 357163
5. **Sherr DH**, Szewczuk MR, Cusano A, Rappaport W, Siskind GW. Ontogeny of B lymphocyte function. IX. Difference in the time of maturation of the capacity of B lymphocytes from fetal and neonatal mice to produce a heterogeneous antibody response to thymic-dependent and thymic-independent antigens. *Immunol.* 1979; 36:891. PMCID: PMC1457667
6. Cheung N-K, **Sherr DH**, Heghinian KM, Benacerraf B, Dorf ME. Immune suppression in vivo“ with antigen-modified syngeneic cells. I. T-cell mediated suppression to the terpolymer poly-(Glu, Lys, Phe). *J Exp Med.* 1978; 148:1539. PMCID: PMC2185101
7. Szewczuk MR, **Sherr DH**, Cornachia A, Kim YT, Siskind GW. Ontogeny of B lymphocyte function. XI. The secondary response by neonatal and adult B-cell populations to different T-dependent antigens. *J Immunol.* 1979; 122:1294. PMID: 87429
8. **Sherr DH**, Cheung N-KV, Heghinian KM, Benacerraf B, Dorf ME. Immune suppression in vivo“ with antigen-modified syngeneic cells. II. T cell mediated nonresponsiveness to fowl gamma globulin. *J Immunol.* 1979; 122:1899. PMID: 87447

9. **Sherr DH**, Heghinian KM, Benacerraf B, Dorf ME. Immune suppression in vivo with antigen-modified syngeneic cells. III. Distinctions between T-cell tolerance and T cell mediated suppression. *J Immunol.* 1979; 123:2682. PMID: 91641
10. **Sherr DH**, Heghinian KM, Benacerraf B, Dorf ME. Immune suppression in vivo with antigen-modified syngeneic cells. IV. Requirement for Ia⁺ adherent cells for induction. *J Immunol.* 1980; 124:1389. PMID: 6153681
11. **Sherr DH**, Benacerraf B, Dorf ME. Immune suppression in vivo with antigen modified syngeneic cells. V. Interacting T-cell subpopulations in the suppressor pathway. *J Immunol.* 1980; 125:1862. PMID: 6997388
12. **Sherr DH**, Ju S-T, Weinberger JZ, Benacerraf B, Dorf ME. Hapten-specific T cell responses to 4-hydroxy-3-nitrophenyl acetyl. VII. Idiotype-specific suppression of plaque-forming cell responses. *J Exp Med* 1981; 153:640. PMID: PMC2186094
13. **Sherr DH**, Dorf ME. Hapten-specific responses to 4-hydroxy-3-nitrophenyl acetyl. IX. Characterization of idiotype specific effector phase suppressor cells on plaque forming cell responses in vitro. *J Exp Med* 1981; 153:1445. PMID: PMC2186186
14. **Sherr DH**, Francus T, Szewczuk MR, Kim YT, Sogn D, Siskind GW. Ontogeny of B lymphocyte function. X. Strain differences in maturation of the capacity of the B lymphocyte population to produce a high-affinity antibody response. *Eur J Immunol.* 1981; 11:32. PMID: 6163636
15. **Sherr DH**, Huber BT, Gershon RK, Benacerraf B, Dorf ME. Effect of anti-Lyb 3 antiserum on poly (L-glutamic acid, L-lysine)-induced B cell tolerance. *Eur J Immunol.* 1981; 11:241. PMID: 6165589
16. Okuda K, Minami M, **Sherr DH**, Dorf ME. Hapten-specific T cell responses to 4-hydroxy-3-nitrophenyl acetyl. XI. Pseudogenetic restrictions of hybridoma suppressor factors. *J Exp Med.* 1981; 154:468. PMID: PMC2186408
17. **Sherr DH**, Ju S-T, Dorf ME. Hapten-specific T cell responses to 4-hydroxy-3-nitrophenyl acetyl. XII. Fine specificity of anti-idiotypic suppressor T cells (TS2). *J Exp Med.* 1981; 154:1382. PMID: PMC2186514
18. **Sherr DH**, Dorf ME. Hapten-specific T cell responses to 4-hydroxy-3-nitrophenyl acetyl. XIII. Characterization of a third T cell (TS3) involved in suppression of in vitro PFC responses. *J Immunol.* 1982; 128:1261. PMID: 6173430
19. Furusawa S, Minami M, **Sherr DH**, Dorf ME. Analysis of the suppressor T cell cascade with products derived from T cell hybridomas. In *Cell Fusion*, Beers RF, Bassett FG, eds. Raven Press. 1982.

20. **Sherr DH**, Minami M, Okuda K, Dorf ME. Analysis of T cell hybridomas. III. Distinctions between two types of hapten-specific suppressor factors which effect plaque forming cell responses. *J Exp Med.* 1983; 157:515. PMID: PMC2186932
21. **Sherr DH**, Onyon ME, Dorf ME. Role of idiotypes in the 4-hydroxy-3-nitrophenyl acetyl (NP)-specific suppressor T cell pathway. In: *Idiotypes-Structures and Functions*, Nisonoff A, Green MI, eds. New York: Plenum Publishing Co., 1984, P.449.
22. **Sherr DH**, Dorf ME. An idiotypic specific helper population which bears immunoglobulin, Ia and Lyt-1 determinants. *J Exp Med.* 1984; 159:1189. PMID: PMC2187269
23. **Sherr DH**, Dorf ME. Characterization of anti-idiotypic suppressor T cells (T_{sid}) induced following antigen priming. *J Immunol.* 1984; 133:1142. PMID: 6205068
24. **Sherr DH**, Vietor HE, Liu Y-N, Dorf ME. Hapten-specific T cell responses to 4-hydroxy-3-nitrophenyl acetyl. XIV. Carrier requirement for suppressor cell induction. *J Immunol.* 1984; 133:2417. PMID: 6207229
25. Dorf ME, Usui M, **Sherr DH**. Use of suppressor cell hybridomas to dissect T cell interactions. In: *T cell clones*, H Von Boehmer, W. Hass, eds. Amsterdam: Elsevier, 1985, p.41.
26. **Sherr DH**, Dorf ME. H-2 restricted helper activity mediated by immunoglobulin bearing lymphocytes. *J Immunol.* 1985; 134:2084. PMID: 3156178
27. Hausman PB, **Sherr DH**, Dorf ME. An in vitro system for the generation of suppressor cells and the requirement for B cells in their induction. *J Immunol.* 1985; 134:1388. PMID: 2578504
28. Hausman PB, **Sherr DH**, Dorf ME. Regulation of hapten specific T and B cell responses by suppressor T cells. *Concepts in Immunopathol.* 1985; 3:38. PMID: 2954643
29. Hausman PB, **Sherr DH**, Dorf ME. Mechanism controlling the genetic restriction of an NP-specific suppressor factor which inhibits B cell responses. *J Immunol.* 1985; 135:915. PMID: 2409159
30. Hausman PB, **Sherr DH**, Dorf ME. Anti-idiotypic B cells are required for the induction of suppressor T cells. *J Immunol.* 1986; 136:48. PMID: 2415628
31. **Sherr DH**, Ju S-T. Idiotypic-specific helper cells (B_H-) express immunoglobulin markers and employ T cell function associated molecules. *J Immunol.* 1986; 137:3406. PMID: 2946760
32. Hausman PB, Kawasaki H, O'Hara RM Jr, Minami M, **Sherr DH**, Dorf ME. The role of adherent accessory cells in the generation of effector suppressor T cells. *J Immunol.* 1986;137:3717. PMID: 2946768

David Sherr, Ph.D.

33. **Sherr DH**, Braun J, Dorf ME. B helper cell hybridomas. Idiotypic specific Ly-1 B cell mediated helper activity. *J Immunol.* 1987. 138:2057. PMID: 3494058
34. **Sherr DH**, Dorf ME, Gibson M, Sidman CL. Ly-1 B helper cells in autoimmune "viable motheaten" mice. *J Immunol.* 1987 138:1811. PMID: 2957439
35. O'Hara RM, Hausman, P.B., **Sherr DH**, Abromson-Leeman, S. R., Dorf ME. A role for L3T4⁺ T cells and their lymphokines in the generation of suppressor effector (Ts3) cells. 1988. *Cell Immunol.* 116:423. PMID: 2972390
36. O'Hara RM, **Sherr DH**, Dorf ME. In vitro generation of suppressor T cells: Induction of CD3⁺, IgH-restricted suppressor cells. 1988. *J. Immunol.* 141:2935. PMID: 2459234
37. **Sherr, DH**. Immune function in the weightless environment. 1989. in "Space Life Sciences," MIT press.
38. Gibson M, Hardin JA, **Sherr DH**, CD5⁺ B helper cell hybridomas produce a lymphokine which induces CD5⁺ B helper cell populations. 1990, *J. Mole. and Cell. Biol.* 4:241. PMID: 1698380
39. Hardin JH, Gibson M, Kawano Y, Spielberg S, Martin C, Collins M, Dorf ME, **Sherr DH**. Characterization of a B cell helper factor(s) derived from CD5⁺ B cell hybridomas. 1990, *Cell. Immunol.* 126:304. PMID: 1690081
40. Hardin J, Voss K, Kawano Y, **Sherr DH**. A function for Ly-1⁺ B cells. 1990, *Proc. Soc. for Exp. Biol and Med.* 195:172. PMID: 2146687
41. Hardin, J, Gibson M, Grant, E, **Sherr DH**. 1992. Interleukin 4 induces functional, CD5⁺ B cells. *Proc. Soc. Exp. Biol. Med.* 200:383. PMID: 1377393
42. Hinoshita, F, Hardin, J, **Sherr DH**. 1992. Fluoranthene induces programmed cell death in and alters growth of immature B cell populations in bone marrow cultures. *Toxicology*, 73:203. PMID: 1609430
43. Hardin J., **Sherr DH**, DeMaria M, and Lopez P. 1992. A simple fluorescence method for detecting apoptosis in cell subsets stained for surface antigen expression. *J. Immunol. Meth.* 154:99. PMID: 1401949
44. Hardin J, Hinoshita F, **Sherr DH**. 1992. Mechanisms by which benzo(a)pyrene, an environmental carcinogen, suppresses B cell lymphopoiesis. *Toxicol. and Applied Pharmacol.* 117:155 PMID: 1335172
45. Peng, B, **Sherr DH**, Mahboudi, F, Hardin, J, Wu, Y-H, Sharer L, Raveche, E. 1994. A cultured malignant B-1 line serves as a model for Richter's Syndrome. *J. Immunol.* 153:1869. PMID: 8046247

46. Hardin J, Yamaguchi K, and **Sherr DH**. 1995. The role of peritoneal stromal cells in the survival of sIgM⁺ peritoneal B lymphocyte populations. *Cell. Immunol.* 161:50-60. PMID: 7867085
47. Ju S-T, Panka DJ, Cui H, Ettinger R, El-Khatib M, **Sherr DH**, Stanger BZ, and Marshak-Rothstein, A. 1995. The molecular mechanism of programmed cell death following T cell activation requires Fas/FasL interactions. *Nature.* 373:444. PMID: 7530337 (6th most cited manuscript of 1995 with over 1200 citations).
48. Cui H, **Sherr DH**, El-Khatib M, Matsui K, Panka DJ, Marshak-Rothstein A, Ju S-T. 1996. Regulation of T-cell death genes: Selective inhibition of FasL- but not Fas-mediated function. *Cell. Immunol.* 167:276 PMID: 8603437
49. Cui H, El-Khatib M, **Sherr DH**, Ettinger R, Sy M-S, Marshak-Rothstein A, Ju S-T. 1996. Characterization of LPR-derived T cell hybridomas: Fas-death deficient hybridomas are deathless, growth-arrested, and cytotoxic upon activation. *Cell Immunol.* 167:302. PMID: 8603440
50. Yamaguchi K, Near R, Shneider A, Cui, H., Ju S-T, and **Sherr DH**. 1996. Fluoranthene mediated apoptosis in murine T cell hybridomas is aryl hydrocarbon receptor independent. *Toxicol. and Appl. Pharmacol.* 139:144. PMID: 8685897
51. Wu M, Lee H, Bellas RB, Schauer SL, Arsura M, Katz D, Fitzgerald MJ, Rothstein TL, **Sherr DH**, Sonenshein GE. 1996. Inhibition of NF- κ B/Rel induces apoptosis of murine B cells. *EMBO. J.* 15:101. PMCID: PMC452200
52. Wu M, Arsura M, Bellas, RE, FitzGerald, MJ, Lee H, Schauer SL, **Sherr, DH** and Sonenshein GE. 1996. Inhibition of c-myc expression induces apoptosis of WEHI 231 murine B cells. *Molec. Cell. Biol.* 16:5015. PMCID: PMC231503
52. Cui, H., Ju, S-T, and **Sherr DH**, 1996. Functional expression of Fas (CD95) protein in autoimmune lpr mice. *Cell. Immunol.* 174:35-41. PMID: 8929452
53. Vaziri, C, Shneider, A., **Sherr, DH.**, and Faller, D. 1996. Expression of the aryl hydrocarbon receptor is regulated by serum and mitogenic growth factors in murine 3T3 fibroblasts. *J. Biochem.* 271:25921. PMID: 8824226
54. Yamaguchi K, Near R, Matulka R, Shneider A, Toselli, P, Trombino, A.F., and **Sherr DH**. 1997. Activation of the aryl hydrocarbon receptor/transcription factor and bone marrow stromal cell-dependent preB cell apoptosis. *J. Immunol.* 158: 2165 PMID: 9036962
55. Yamaguchi, K., Matulka, RA, Shneider A., Toselli, P., Trombino, AF, Yang, S, Hafer, LJ., Mann, KK., Tao, X-J., Tilly, JL., Near R., **Sherr DH**, 1997. Induction of preB cell apoptosis by 7,12 dimethylbenz[*a*]anthracene in long term primary bone marrow cultures. *Toxicology and Applied Pharmacology.* 147:190. PMID: 9439715

56. Near, R.I., Matulka, R.A., Mann, K.K., Shneider, A.M. Gogate, S.U., Trombino, A.F., and **Sherr DH**. 1999. Regulation of preB cell apoptosis by aryl hydrocarbon receptor/transcription factor-expressing stromal/adherent cells: Proceedings of the Society for Experimental Biology and Medicine. 221:242-252 PMID: 10404042
57. Mann K., Matulka R, Lawrence BP, Kerkvliet, N, Trombino AF, Hahn M, and **Sherr, DH**. 1999. The role of polycyclic aromatic hydrocarbon metabolism in dimethylbenz[*a*]anthracene-induced pre-B lymphocyte apoptosis. Toxicol. Appl. Pharmacol. 161:10-22. PMID: 10558919
58. Robles, R, Morita, Y, Mann, KK, Perez, GI, Yang, S, Matikainen, T, **Sherr, DH**, Tilly, JL. 2000. The aryl hydrocarbon receptor, a basic helix-loop-helix transcription factor of the PAS gene family, is required for normal ovarian germ cell dynamics in the mouse. Endocrinology. 141:450-453. PMID: 10614669
59. Trombino AF, Near, RI, Matulka, RA, Yang S, Hafer, LJ, Toselli, PA, Kim D, Sovak, M, Rogers A, Sonenshein G, **Sherr DH**. 2000. Expression of the aryl hydrocarbon receptor/transcription Factor (AhR) and AhR-regulated *CYP1* gene transcripts in a rat model of mammary tumorigenesis. Breast Cancer Research and Treatment, 62:117-131. PMID: 11097088
60. Quadri S, Qadri A, Hahn ME, Mann KK, **Sherr DH**. 2000. The bioflavonoid galangin blocks aryl hydrocarbon receptor (AhR) activation and polycyclic aromatic hydrocarbon-induced pre-B cell apoptosis. Molec. Pharmacol. 58:515-525. PMID: 10953044
61. Kim, DW, Gazourian, L, Quadri, SA, **Sherr, DH**, Sonenshein, GE. 2000. The aryl hydrocarbon receptor/transcription factor (AhR) and the Rel A nuclear factor- κ B subunit cooperate to transactivate the c-myc promoter. Oncogene. 19:5498-5506. PMID: 11114727
62. Jodo S, Hohlbaum A, Xiao S, Chan D, Strehlow D, **Sherr DH**, Marshak-Rothstein, M and Ju S-T. 2000. CD 95 ligand (FasL)-expressing vesicles display antibody-mediated, FcR-dependent enhancement of cytotoxicity. J. Immunol. 165:5487-5494. PMID: 11067901
63. Mann KK, Doerre, S, **Sherr DH**, Quadri S. 2001. The role of NF- κ B as a survival factor in environmental chemical-induced preB cell apoptosis. Molec. Pharmacol. 59:302-309. PMID: 11160867
64. Kavanagh KT, Hafer LJ, Kim DW, Mann KK, **Sherr DH**, Rogers AE, Sonenshein GE. 2001. Green tea extracts decrease carcinogen-induced mammary tumor burden in rats and rate of breast cancer cell proliferation in culture. J. Cell. Biol. 82:387-398. PMID: 11500915
65. Matikainen T, Perez, GI, Jurisicova A, Mann KK, Schlezinger JJ, Ryu H-Y, Sakai T, Korsmeyer SJ, Casper RF, **Sherr DH**, Tilly JT. 2001, Dioxin receptor-dependent *bax* gene transcription is required for ovarian failure caused by biohazardous environmental chemicals. Nature Genetics. 28:355-360. PMID: 11455387

66. Matikainen, TM, Moriyama T, Morita Y, Perez, GI, Korsmeyer SJ, **Sherr, DH**, Tilly, JL. 2001. Ligand activation of the aromatic hydrocarbon receptor (AHR)-transcription factor drives Bax-dependent apoptosis in developing fetal ovarian germ cells. *Endocrinology*. 143:615-620 PMID: 11796517
67. Schlezinger JJ, Jensen BA, Mann KK, Ryu H-Y, **Sherr DH**. 2002. Peroxisome proliferator-activated receptor γ -mediated NF- κ B activation and apoptosis in pre-B cells. *J.Immunol*. 169:6831. PMID: 12471115
68. Takai, Y., J. Canning, G. I. Perez, J. K. Pru, J. J. Schlezinger, **Sherr, DH**, R. N. Kolesnick, J. Yuan, R. A. Flavell, S. J. Korsmeyer, and J. L. Tilly. 2003. Bax, caspase-2, and caspase-3 are required for ovarian follicle loss caused by 4-vinylcyclohexene diepoxide exposure of female mice *in vivo*. *Endocrinology* 144:69-74. PMID: 12488331
69. Maecker B, **Sherr DH**, Vonderheide RH, von Bergwelt-Baildon M, Hirano N, Anderson KS, Xia Z, Butler MO, Wucherpfeiff KW, O'Hara C, Cole G, Ramstedt U, Tomlinson AJ, Chiczy RM, Nadler LM, and Schultze JL. 2003. The shared tumor associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells. *Blood*. 102:3287. PMID: 12869499
70. Ryu, K-Y, Mann KK, Schlezinger JJ, Jensen B, **Sherr, DH**. 2003. Environmental chemical-induced pre-B cell apoptosis: analysis of c-Myc, p27^{Kip1}, and p21^{WAF1} reveals a death pathway distinct from clonal deletion. *J. Immunol*. 170:4897-4904 PMID: 12734332
71. Allan, LL, Mann, KK, Schlezinger, JL, **Sherr, DH**. 2003. Bone marrow interactions in polycyclic aromatic hydrocarbon-induced pro/pre-B cell apoptosis. *Toxicol. Sci*. 76:357. PMID: 14514961
72. Jensen, B A, Leeman, RJ, Schlezinger, JJ, **Sherr, DH**. 2003. Aryl hydrocarbon receptor (AhR) agonists suppress interleukin-6 expression by bone marrow stromal cells. *Env. Health. J*. 2:16. PMCID: PMC317352
72. Webster T and **Sherr DH**. 2003. Types of AhREs and their implications. *Organohalogen Compounds* 65:106
73. **Sherr DH**. 2004. 2,3,7,8-Tetrachloro-*p*-dioxin (TCDD) and long term immunologic memory. *Toxicol. Sci*. 79:211 PMID: 15185717
74. Xiao, S, Zhang X, Mann KK, Jodo S, **Sherr DH**, Marshak-Rothstein A, and Ju S-T. 2004. Mechanisms of CD4⁺CD8⁺B220⁺ T cell deletion. *Int. Immuno*. 16:759 PMID: 15096479
75. Schlezinger, JJ, Hurst CH, Waxman DJ, **Sherr DH**. 2004. Mono-2-ethylhexylphthalate, an environmental PPAR γ agonist, induces growth arrest and apoptosis in pro/pre-B cells. *J. Immunol*.173:3165. PMID: 15322177.
76. Tiwari, S, Felekkis K, Moon EY, Flies A, **Sherr DH**, and Lerner A. 2004. Among circulating hematopoietic cells, B-CLL uniquely expresses functional EPAC1, but EPAC1-

David Sherr, Ph.D.

mediated Rap1 activation does not account for PDE4 inhibitor-induced apoptosis. *Blood*. 103:2661. PMID: 14615375

77. Maecker B, von Bergwelt-Baildon MS, **Sherr DH**, Nadler LM, Schultze JL. Identification of a new HLA-A*0201 restricted cryptic epitope from CYP1B1. 2005. *International Journal of Cancer*. 115:333 PMID: 15688394

78. Murray SA, Yang S, Demicco E, Ying H, **Sherr DH**, Hafer LJ, Rogers AE, Sonenshein GE, and Xiao Z-X J. 2005. Increased expression of MDM2, cyclin D1, and p27^{Kip1} in carcinogen-induced rat mammary tumors. *J. Cell Biochem*. 95:875. PMID: 15844214

79. Schaefer KL, Senevich S, Ma C, Cooley SR, Nakajima A, Wada, K, Schlezinger JJ, **Sherr DH**, and Saubermann LJ. 2005. Intestinal anti-inflammatory effects of thiazolidenedione PPAR γ ligands on Th1 chemokine regulation include non-transcriptional control mechanisms. *Inflammatory Bowel Diseases*. 11:244. PMID: 15735430

80. Allan L and **Sherr DH**. 2005. Constitutive activation and environmental chemical induction of the aryl hydrocarbon receptor/transcription factor (AhR) in activated human B lymphocytes. *Mol. Pharmacol*. 67:1740. PMID: 15681594

81. Yang X, Murray TJ, Liu D, Mitchell GC, Hesterman EV, Karchner SI, Hahn ME and **Sherr DH**. 2005. The aryl hydrocarbon receptor/transcription factor constitutively represses *c-myc* transcription in human mammary tumor cells. *Oncogene*. 24:7869. PMID: 16091746

82. Ryu H-Y, Emberley J, Schlezinger J, Allan LL, Na S, and **Sherr DH**. 2005. Environmental chemical-induced bone marrow B cell apoptosis: Death receptor-independent activation of a caspase-3 to caspase-8 pathway. *Molecular Pharmacology*. 68:1087. PMID: 16014577

83. Currier N, Solomon S, Demicco E, Chang D, Farago M, Ying H, Dominguez I, Sonenshein GE, Cardiff R, Xiao J, **Sherr DH**, and Seldin DC. 2005. Oncogenic signaling pathways activated in DMBA-induced mouse mammary tumors. *Toxicologic Pathology*. 33:726. PMID: 16263698

84. Shin SR, Sanchez-Velar N, **Sherr DH**, and Sonenshein GE. 2006. 7,12-Dimethylbenz[*a*]Anthracene treatment of a *c-rel* mouse mammary tumor cell line induces epithelial to mesenchymal transition via activation of NF- κ B. *Cancer Research*. 66:2570. PMID: 16510574

85. Allan LL, Schlezinger J, Shansab M, and **Sherr DH**. 2006. CYP1A1 in polycyclic aromatic hydrocarbon-induced B lymphocyte growth suppression. *Biochem Biophys Res Commun*. 342:227. PMID: 16472762

86. Murray TJ, Yang X, and **Sherr DH**. 2006. Growth of a human mammary tumor cell line is blocked by galangin, a naturally occurring bioflavonoid, and is accompanied by down-regulation of cyclins D3, E, and A. *Breast Cancer Res*. 8:R17. PMCID: PMC1557718

87. Schlezinger JJ, Emberley J, and **Sherr DH**. 2006. Activation of multiple MAP Kinases in pro/pre-B cells by GW7845, a PPAR γ agonist, and their contribution to GW7845-induced apoptosis. *Toxicological Sciences*. 92:433. PMID: 16672323
88. Schlezinger JJ, Liu D., Farago M, Seldin DC, Belguise K, Sonenshein G, and **Sherr DH**. (2006). A role for the aryl hydrocarbon receptor in mammary gland tumorigenesis. *Biological Chemistry*. 387:1175-87. PMID: 16972784
89. Schlezinger JJ, Emberley J, Bissonette S, and **Sherr DH**. 2007. An l-tyrosine derivative and PPAR γ agonist, GW7845, activates a multi-faceted caspase cascade in bone marrow B cells. *Toxicological Sciences*. 98:125-136 PMID: 17400580
90. Yang X, Solomon S, Fraser LR, Trombino AF, Liu D, Sonenshein GE, Hestermann EV, and **Sherr DH**. 2007. Constitutive regulation of CYP1B1 by the aryl hydrocarbon receptor (AhR) in pre-malignant and malignant mammary tissue. *J. Cell. Biochem*. 104:402-417. PMID: 18059014
91. Belguise K, Guo S, Yang S, Rogers AE, Seldin DC, **Sherr DH**, and Sonenshein GE. 2007. Green tea polyphenols reverse cooperation between c-Rel and CK2 that induces the aryl hydrocarbon receptor, slug, and an invasive phenotype. *Cancer Res* 67:11742-11750. PMID: 18089804
92. Ahmadi T, Efebera Y, and **Sherr DH**. 2007: CD40 ligand-activated, antigen-specific B Cells are comparable to mature dendritic cells in presenting protein antigens and MHC class I- and class II-binding peptides. *Immunology*. 124:129-140 PMID: PMC2434387
93. Min C, Eddy SF, **Sherr DH**, and Sonenshein, GE. 2008. NF- κ B and epithelial mesenchymal transition of cancer. *J. Cell. Biochem*. 104: 733-744. PMID: 18253935
94. Evans, B. R., S. I. Karchner, L. L. Allan, R. S. Pollenz, R. L. Tanguay, M. J. Jenny, **D. H. Sherr**, and M. E. Hahn. 2008. Repression of aryl hydrocarbon receptor (AHR) signaling by AHR repressor: role of DNA binding and competition for AHR nuclear translocator. *Mol. Pharmacol*. 73:387-398. PMID: 18000031
95. Bissonnette S, Emberley J, **Sherr DH**, and Schlezinger JJ. 2008. Overlapping but distinct apoptosis signaling pathways induced by an environmental (MEHP) and an endogenous (15d-PGJ2) PPAR γ agonist. *J. Immunol*. 181:1728-36 PMID: PMC2494875
96. Hahn ME, Allan LL, **Sherr DH**. 2009. Regulation of constitutive and inducible AhR signaling: Complex interactions involving the AhR repressor. *Biochem Pharmacol*. 77:485-497 PMID: PMC2701375
97. Karchner S, Jenny M, Franks D, Evans B, Tarrant A, Kang A, Bae I, **Sherr DH**, and Hahn ME. 2009. The active form of human aryl hydrocarbon receptor repressor lacks exon 8 and its Pro185 and Ala185 variants repress both AHR and HIF. *Molec. Cell. Biol*. 13:3465. PMID: PMC2698758

David Sherr, Ph.D.

98. Teague, J., Ryu H-Y, M. Kirber, **Sherr, DH** and J. Schlezinger. 2010. Proximal events in 7,12-dimethylbenz[*a*]anthracene-induced, stromal cell-dependent bone marrow B cell apoptosis: Stromal cell-B cell communication, p53 induction and mitochondrial permeabilization. *J. Immunol.* 185:3369-3378 (Featured on J.I. cover) PMID: 20720205
99. Schlezinger, JJ, Bernard P, Haas A, Grandjean P, and **Sherr DH**. 2010. Direct assessment of cumulative aryl hydrocarbon receptor agonist activity in sera from experimentally exposed mice and environmentally exposed humans. *Environmental Health Perspectives*, 118:693-698. PMID: 20435556 PMCID: PMC2866687
100. Allan LL and **Sherr DH**. 2010. Disruption of human plasma cell differentiation by an environmental polycyclic aromatic hydrocarbon: a mechanistic immunotoxicological study. *Environmental Health* 9:15. PMID: 20334656 PMCID: PMC2851679
101. Apetoh L, Quintana FJ, Pot C, Joller N, Xiao S, Kumar D, Burns EJ, **Sherr DH**, Weiner HL, and Kuchroo VK. 2010. The aryl hydrocarbon receptor (AhR) interacts with c-Maf to promote the differentiation of IL-27-induced regulatory type 1 (Tr1) cells. *Nature Immunology*. 11: 854-861. PMID: 20676095 PMCID: PMC2940320
102. Ehrlich DJ, McKenna BK, Evans JG, Kina A, Denis GV, **Sherr DH**, and Ching Cheung M. 2010. Parallel imaging microfluidic cytometry. *Methods in Cell Biology*. PMID: 21704835
103. Flies A , Ahmadi T, Parks AJ, Prokaeva T, Weng L, Rolfe SS, Seldin DC, and. **Sherr DH**. 2012. Immunoglobulin light chain, Blimp-1 and cytochrome P4501B1 peptides as potential vaccines for AL amyloidosis. *Immunol Cell Biol* 90:528-539. PMID: 21894172
104. Selmi C LP, **Sherr DH.**, Dias M, Nyland J, Rose N and Gershwin ME. 2012. The role of the environment in the development of autoimmune disease: an NIEHS Expert Panel Workshop. *J. Autoimmunity*. 39:272 PMID: 22749494
105. Smith, BW, Rozelle, SS, Leung A, Ubellacker J, Parks A, Nah SK, French D, Gadue P, Monti S, Shui DHK, Steinberg MH, Frelinger AL, Michelson AD, Theberge R, McComb ME, Costello CE, Kotton, DN, Mostoslavsky G, **Sherr DH**, and Murphy GJ. The aryl hydrocarbon receptor directs hematopoietic progenitor cell expansion and differentiation. 2013. *Blood*: 122:376-385
106. Quintana, F and **Sherr, DH**. 2013. Endogenous AhR ligands and their role in autoimmunity. *Pharmacological Reviews*. 65:1148-1161
107. Monti, S and **Sherr DH**. 2013. The role of the aryl hydrocarbon receptor in normal and malignant B cell development. *Seminars in Immunopathology* 35:705-716.
108. Lowe, MM., Mold, JE, Kanwar B, Huang Y, Louie A, Pollastri MP, Wang C, Franks DG, Schlezinger JJ, **Sherr DH**, Silverstone AE, Hahn ME, and McCune JM. 2013. Identification of Cinnabarinic Acid as a Novel Endogenous Aryl Hydrocarbon Receptor Ligand That Drives Th22 DifferentiationIL-22 Production *PLOS One* 9:e87877.

109. Parks, A., Pollastri M, Frangs D, Haigh-Molina S, Ashton T, Ubellacker J, Stanford E Schlezinger JJ, and **Sherr DH**. 2013. Identification of a novel AhR antagonist that blocks breast cancer invasion in vitro and acute AhR-mediated DMBA toxicity in vivo. *Mole. Pharmacol.* 86:593-608
110. Gusenleitner, D., Auerbach S, Tice R, **Sherr DH**, and Monti S. 2014. Genomic models of short-term exposure accurately predict long-term chemical carcinogenicity. *PLOS One*. 9:e102579.
111. Grandjean, P., Barouki, R., Bellinger, D, Casteleyn, L, Chadwick, L, Cordier, S, Etzel, R, Gray, K, Ha, E-H, Junien, D, Karagas, M, Kawamoto, T, Lawrence, BP, Perera, F, Prins, GS, A. Puga, A, Rosenfeld, C, **Sherr, DH**, Sly, P, Suk, W, Sun, Q, Toppari, J, van den Hazel, P, Walker C, and Heindel J. 2015. Life-long implications of developmental exposure to stressors and the research perspective. *Endocrinology* Epub EN20151350 8/2015
112. Shivanna, S., Kolandaivelu K, Moshe S, Novikov O, Balcells M, Zheng A, Weinberg J, Francis J, Edelman ER, **Sherr DH**, and VC. Chitalia. 2016. The aryl hydrocarbon receptor is a critical regulator of tissue factor stability and is a novel anti-thrombotic target in uremia. *J.Am.Soc. Neph.* 27:189-201. PMC4696580
113. Stanford E., Wang Z, Novikov O, Mulas F, Landesman-Bolag E., Monti S, Smith B, Muprhy GJ, and **Sherr DH**. 2016. The role of the aryl hydrocarbon receptor in the development of cells with molecular and functional characteristics of breast cancer stem cells. *BMC Biology.* 14:20.
114. Smith BW, Stanford EA, **Sherr DH**, Murphy GJ: Genome editing of the *Cyp1a1* locus in iPSCs as a platform to map AHR expression throughout human development. *Stem Cell International* 2016, 2016:2574152. PMID: 27148368
115. Stanford, EA, Ramirez-Cardenas, A, Wang, Z., Novikov, Alamoud, K, Koutrakis, P, Mizgerd, JP, Genco, CA, O, Kukuruzinska, MA, Monti, S, Bais, MV, and **Sherr, DH**. 2016. The role of the aryl hydrocarbon receptor and its diverse ligands in oral cancer cell migration and tumorigenesis. *Molecular Cancer Research, In Press*
116. Novikov O, Wang Z, Stanford EA, Parks AJ, Ramirez-Cardenas A, Gusenleitner D, Li A, Monti S, Manteiga S, Lee K, and **Sherr DH**. 2016. An aryl hydrocarbon receptor-mediated positive feedback loop that enforces cell migration in ER⁺/PR⁻/Her2⁻ human breast cancer cells. *Molecular Pharmacology, In Press*.
117. Chen, H-R, **Sherr DH**, Hu Z, DeLisi C. 2016. A network based approach to drug repositioning identifies plausible candidates for breast cancer and prostate cancer. *BMC Medical Genomics: In Press*
118. Mulas F, Li A, **Sherr DH**, Monti S. 2016. Network-based analysis of transcriptional profiles from chemical perturbation experiments. *BMC Bioinformatics. In Press*.

David Sherr, Ph.D.

119. Narasimhan, S., Gusenleitner D, Monti S, Rolfe S, Schlezinger JJ, and **Sherr DH**. 2016. The aryl hydrocarbon receptor regulates human mammary tumor cell invasion. Manuscript in preparation.

Invited Editorials (since 2004)

Sherr DH. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) and long term immunologic memory. 2004. *Toxicol Sci* 79:211-213.

Sherr DH. Activation of aryl hydrocarbon receptor induces vascular inflammation and promotes atherosclerosis in ApoE^{-/-} mice. 2011. *Athero. Thrombo, Vasc. Biol.* 31:1247

Lawrence, B., and **Sherr DH**. 2012. You AhR what you eat? *Nature Imm.* 13:117

Sherr DH. 2013. Getting breast cancer under control. *International Innovations* p94

Abstracts and short articles (since 1996)

Perez, G.I., Wang, S., **Sherr, D.H.**, and Tilly, J.L. Role of apoptosis and the aryl hydrocarbon receptor (AhR) in toxicity of polycyclic aromatic hydrocarbons (PAHs) in murine antral follicles. *Cell Death in Reproductive Physiology*. Chicago, IL. April, 1996.

Yamaguchi, K., Shneider, A., Ju, S-T., and **Sherr, D.H.** Fluoranthene mediated apoptosis in murine T cell hybridomas is Ah receptor independent. *Society of Toxicology Annual Meeting*, Anaheim, CA. April, 1996.

Matulka, R.A., Yamaguchi, K., Shneider, A., Near, R., Trombino, A.F., and **Sherr, D.H.** Ah receptor expression in bone marrow stromal cells influences DMBA-induced pro-B cell apoptosis. *Society of Toxicology Annual Meeting*, Anaheim, CA. April, 1996.

Vaziri, C., Shneider, A., **Sherr, D.H.**, and Faller, D.V. The aryl hydrocarbon receptor is a serum-inducible gene in murine 3T3 fibroblasts. *Society of Toxicology Annual Meeting*, Anaheim, CA. April, 1996.

Trombino, A.F., Yamaguchi, K., **Sherr, D.H.** and Near, R.I. PAH-induced apoptosis in bone marrow B cells requires supporting stromal cells containing the Ah receptor. *Society of Toxicology Annual Meeting*, Anaheim, CA. April, 1996.

Mann, K.K., Yamaguchi, K., Trombino, A.F., Near, R. and **Sherr, D.H.** DMBA-induced apoptosis of B lymphocytes from murine bone marrow cultures. *Society of Toxicology Annual Meeting*, Anaheim, CA. April, 1996.

David Sherr, Ph.D.

Mann, K.K., Matulka, R, Trombino, A.F., Near, R., and **Sherr, D.H.** Requirement of stromal cells in PAH-induced apoptosis of preB cells. American Association of Immunologists Annual Meeting. Atlanta, GA. 1996. FASEB. J.

Trombino, AF, Yang, S., Hafer L.J., Qadri, A.N., Rogers, A.E. and **Sherr, D.H.** 1997. Modulation of aromatic hydrocarbon receptor expression in 7,12-dimethylbenz[*a*]anthracene-induced rat mammary tumors. Society of Toxicology Annual Meeting, Anaheim, CA. April, 1997. *The Toxicologist*.

Shneider, A.M., and **Sherr, D.H.** 1997. Benzo(a)pyrene induces NF- κ B in mouse hepatoma cells. Society of Toxicology Annual Meeting, Anaheim, CA. April, 1997. *The Toxicologist*.

Near R.I., Matulka, R, Shneider A., Mann, K.K., and **Sherr, D.H.** 1997. Apoptosis signals mediated via the aromatic hydrocarbon receptor (AhR) have different efficacy with different stromal lines and toxins. Society of Toxicology Annual Meeting, Anaheim, CA. April, 1997. *The Toxicologist*.

Mann, K.K., Trombino, A.F., Lawrence, B.P., Kerkvliet, N.I., and **Sherr, D.H.** 1997. DMBA-induced pre-B cell apoptosis is both stromal and AhR-dependent, but not P-450IA mediated. Society of Toxicology Annual Meeting, Anaheim, CA. April, 1997. *The Toxicologist*.

Matulka, R.A., Mann, K.K. and **Sherr, D.H.** 1998. DMBA (7,12-dimethylbenzanthracene) induces preB cell death via a soluble stromal cell factor. *The Toxicologist*. 42, 190

Quadri, S.A., Qadri, A.N., and **Sherr, D.H.** 1998. Inhibition of polyaromatic hydrocarbon-induced apoptosis in murine pre-B cells by a dietary flavonoid, galangin. *The Toxicologist*. 42, 189.

Mann, K.K., Quadri, S.A., Qadri, A.N., Shneider, A.M. and **Sherr, D.H.** 1998. Involvement of NF- κ B and c-myc in DMBA-induced preB lymphocyte apoptosis. *The Toxicologist*. 42, 189.

Trombino, A. F., Matulka, R.A., Yang, S., Hafer, L.F., Rogers, A.E., and **Sherr, D.H.** 1998. Nuclear expression of the aryl hydrocarbon receptor (AhR) in 7,12-dimethylbenz[*a*]anthracene (DMBA)- induced rat mammary tumors and human breast cancer cell lines. *The Toxicologist*. 42, 316.

Mann, K. K., Hahn, M.E., Trombino, A.F., Lawrence, B.P., Kerkvliet, N.I., and **Sherr, D.H.** 1999. The role of DMBA metabolites in preB cell apoptosis. *The Toxicologist*. 48, 89.

Quadri, S.A., Qadri, A.N., and **Sherr, D.H.**, 1999. Signal transduction in PAH-induced preB cell apoptosis. *The Toxicologist*. 48, 153.

B. Maecker, C. Shen, R.H. Vonderheide, M. von Bergwelt-Baildon, M. Bedor, D. Schnipper, L.M. Nadler, **D.H. Sherr**, and J.L. Schultze. 1999. Induction of tumor-specific CTL responses with a peptide derived from cytochrome P450 1B1, a widely expressed tumor associated protein. *Blood*.

David Sherr, Ph.D.

Maecker, B., R.H. Vonderheide, M. von Bergwelt-Baildon, M. Bedor, C-F. Shen, J.L. Schultze, **D.H. Sherr**. 2000. The AhR and CYP1B1 as targets for peptide/tumor-specific cancer immunotherapy. *Toxicol. Sci.* 54, 351.

Quadri, S.A., D.W. Kim, L. Gazourian, G.E. Sonenshein and **D.H. Sherr**. 2000. The aryl hydrocarbon receptor/transcription factor (AhR) and the Rel A nuclear factor- κ B subunit cooperate to transactivate the *c-myc* promoter. *Toxicol. Sci.* 54, 11.

Trombino, A.F., T.A. Jenkins, R.A. Matulka, R.I. Near and **D.H. Sherr**. 2000. Aryl hydrocarbon receptor ligands modulate MCF-10F breast epithelial cell growth. *Toxicol. Sci.* 54, 50.

Quadri, S.A., Trombino, A.F., Matikainen, T, Perez, G.I., Tilly, J.L., Kim, D.W., Sonenshein, G.E., **Sherr, D.H.** 2001. Cell growth, death, and NF- κ B regulation by the aryl hydrocarbon receptor. *Toxicol. Sci.* 60, 135.

Schlezing, J.J., Jensen, B., Ryu, H-Y, **Sherr, D.H.** 2002. Mechanisms of PPAR γ -mediated pre-B cell apoptosis. *Toxicol. Sci.* 66, 149.

Ryu, H-Y., Schlezing, J.J., Jensen, B.A., **Sherr, D.H.** 2002. DMBA-induced pre-B cell apoptosis: Intracellular signaling pathways. *Toxicol. Sci.* 66, 226.

Yang, X., Murray, T.J., Pachikara, B., Liu, D., Sonenshein, G.E., **Sherr, D.H.** 2002. Aryl hydrocarbon receptor regulation of *c-myc* in human breast cancer cells. AACR Annual Meeting.

Sherr, D.H. 2003. Environmental chemicals and the immune system. Greater Boston Physicians for Social Responsibility newsletter/Human Health and Environment Project.

Emberley, JK, Ryu, H-Y, Allan, LL, Schlezing, JJ, and **Sherr, DH.** 2004. DMBA-Induced Pro/Pre-B Cell Apoptosis: Caspase 8-mediated, TNF Receptor-independent Signaling Pathways. *Toxicol. Sci.* Abstract #1626.

Ryu, H-Y, Emberley, JK, Schlezing, JJ, Allan, LL, and **Sherr, DH.** 2004. Caspase 2 and the Mitochondrion in PAH-Induced Pro/Pre-B Cell Apoptosis
Toxicol. Sci. Abstract #1948

Schlezing, JJ, Emberley, JK, and **Sherr, DH.** 2004. GW7845, a PPAR γ Agonist, Induces MAP Kinase-Dependent Apoptosis in Pro/Pre-B Cells. *Toxicol. Sci.* Abstract #886.

Allan, LL, Ryu, H-Y, Emberley, JK, Schlezing, JJ, and **Sherr, DH.** 2004. AhR Ligands Inhibit Proliferation of Activated Human B cells. *Toxicol. Sci.* Abstract #889.

Sherr, DH, Ryu, H-Y, Emberley, JK, Schlezing, JJ, and Allan, LL. 2004. Cell-Cell Contact is Required for PAH-induced, Stromal Cell-Dependent, Bone Marrow B Cell Apoptosis. *Toxicol. Sci.* Abstract #1625.

David Sherr, Ph.D.

Yang, X., Murray, T.J., Liu, D, and **Sherr, D.H.** 2004. AhR Regulation of c-Myc in Human Breast Cancers. Toxicol. Sci. Abstract #643.

Sherr, DH and Nagarkatti, P. 2005. The AhR in cell growth and death. Toxicol. Sci. 84, S-1, Abstract #990.

Evans, BR, Allan, LL, **Sherr, DH,** and Hahn, ME. 2005. DRE binding is not required for repression of AhR signaling by AhRR. Toxicol. Sci. 84, S-1, Abstract #1359.

Sherr, DH, Ryu, H, Emberley, JK, Allan, LL, and Schlezinger, JJ. 2005. Caspase-8 is not the most proximal caspase involved in DMBA-induced bone marrow B cell apoptosis. Toxicol. Sci. 84, S-1, Abstract #1870.

Allan, LL, Schlezinger, JJ, Shansab, M, and **Sherr, DH.** 2005. The role of PAH metabolism in AhR-dependent inhibition of human B cell proliferation. Toxicol. Sci. 84, S-1, Abstract #1871.

Emberley, JK, Schlezinger, JJ, Ryu, H. and **Sherr, DH.** 2005. The roles of mitochondria and caspase-6 in 7-12-dimethylbenz[*a*]anthracene-induced bone marrow B cell apoptosis. Toxicol. Sci. 84, S-1, Abstract #2288.

Yang, X, Murray, T.J, Liu, D, **Sherr, DH.** 2005. Flavonoid inhibition of mammary tumor growth. DOD Breast Cancer Research Program annual meeting.

Flies A, **Sherr DH.** 2006. A peptide-based vaccine elicits CTL responses towards AL Amyloid-related Immunoglobulin Light Chain. FOCIS Symposium. San Francisco, CA

Emberley JK, Schlezinger, JJ, Ryu, H-Y, and **Sherr, DH.** 2006. DMBA-induced apoptosis of bone marrow B cells is likely initiated through a metabolite-driven, mitochondrial pathway. The Toxicologist. 90, 414.

Schlezinger JJ, Bisonette S, and **Sherr, DH.** 2006. GW7845, a PPAR γ agonist, induces calcium-dependent MAP kinase activation and apoptosis in pro/pre-B cells. The Toxicologist, 90: 355.

Solomon S, Currier, N, Seldin DC, and **Sherr, DH.** .2006. Oncogenic signaling pathways activated in DMBA-induced mammary tumors in mice. The Toxicologist. 90: 140.

Flies, A and **Sherr, DH.** 2006. A novel approach to AL amyloid immunotherapy. XIth International Symposium on Amyloidosis, Amyloid Journal. CRC Press. Eds M. Skinner, J.L. Berk, L.H. Connors, D.C. Seldin.

Sherr DH. 2007. AhR transcriptional regulation and its impact on mammary tumor behavior. SOT annual meeting. Charlotte, NC.

Solomon S, and **Sherr DH.** 2007. Expression of the aryl hydrocarbon receptor and its repressor (AhRR) during mammary tumorigenesis. SOT annual meeting, Charlotte, NC.

David Sherr, Ph.D.

Schlezingner JJ, Bissonnette S, and **Sherr DH**. 2007. GW7845, an L-tyrosine derivative and PPAR γ agonist, induces calcium-driven, mitochondria-dependent apoptosis in pro/pre-B cells. SOT annual meeting, Charlotte, NC.

Emberley J, Schlezingner JJ, Ryu, H-Y, and **Sherr DH**. 2007. The Roles of p53 and the Mitochondrial Pathway in DMBA-Induced Bone Marrow B Cell Apoptosis. Keystone meeting "Apoptotic and Non-Apoptotic Cell Death Pathways", Abs. 144.

Karchner SI, Jenny MJ, Tarrant AM, Evans BR, Yang X, **Sherr DH**, and Hahn ME. 2008. Aryl hydrocarbon receptor repressor (AhRR): Mechanistic insights from studies in mammalian and nonmammalian models. *The Toxicologist*. 102:451

Narasimhan S, and **Sherr DH**. 2008. Role of the aryl hydrocarbon receptor in mammary tumor progression. *The Toxicologist* 102:218

Schlezingner, JJ, Bissonnette, S, Teague, JE and **Sherr, DH** . 2008. Contribution of p53 and Bcl-2 Family Members in Prostaglandin and Phthalate-Induced Pro/Pre-B Cell Apoptosis. *The Toxicologist* 102:124

Lu J and Sherr DH. 2008. A head-to-head comparison in the ability of cyclophosphamide and ontak to reduce the influence of regulatory T cells on self (tumor) peptide-specific CTL responses. *Blood* 112:

Schlezingner JJ, Haas A., and **Sherr DH**. 2009. Tributyltin: A Dual Bone Marrow Stromal Cell and Lymphocyte Toxicant? *The Toxicologist*

Belguise K, Guo S, Mineva ND, Wang X, Yang S, Rogers AE, Seldin DC, **Sherr DH**, Holick MF, and Sonenshein GE. 2009. Green tea and Breast Cancer. Belgium Conference on Cancer Prevention.

Narasimhan S, **Sherr DH**. 2009. A role for the constitutively active AhR in mammary tumor progression. Gordon Conference, Newport RI.

Hahn, ME, Karchner SI, Henny MJ, Evans BR, Stegeman JJ, **Sherr DH**. 2009. Aryl hydrocarbon receptor repressor (AhRR): Mechanistic insights from studies in mammalian and nonmammalian models. Horiba/Center for Disease Biology and Integrative Medicine symposium, Tokyo, Japan.

Schlezingner JJ, Haas AR, Yanik SC, Gerstenfeld LC, **Sherr DH**. 2009. Environmental contaminants skew mesenchymal stem cell differentiation in bone marrow: Examining accelerated aging of bone. Superfund Research Program Annual Meeting, New York, NY.

Yanik, SC, **Sherr DH**, Schlezingner JJ. 2010. Organotin-mediated PPAR γ activation and adipocyte differentiation in bone marrow stromal cells. *The Toxicologist* (Supp) #1551.

David Sherr, Ph.D.

Haas AR, Yanik SC, **Sherr DH**, Gerstenfeld LC, and Schlezinger JJ. 2010. Tributyltin: B cell toxicant and bone marrow microenvironment modulator. *The Toxicologist* (Supp) #1549.

Parks, AH, Pollastri MP, Hahn ME, Franks DG, Haigh-Molina S, Harasimhan S, Schlezinger JJ, Sherr DH. 2012. Inhibition of dimethylbenz[a]anthracene-induced bone marrow toxicity with a novel aryl hydrocarbon receptor inhibitor. Boston University Science Day

Gusenleitner D, Melia T, Gomez H, Benson G, Sherr DH, Monti S. 2012. Genomic signatures of carcinogenicity. Boston University Science Day. Winner, Dean of the College of Science, Best Poster.

Novikov O, Parks A, Narasimhan S, Rolf S, Stanford E, Ubellacker J., **Sherr DH**. 2013. The role of environmental and endogenous ligands in tumor invasion and metastasis. Keystone National MD/PhD Student Conference.

Gusenleitner D, Auerbach S, Sherr DH, Monti S. 2013. Genomic signatures of carcinogenicity. 13th International Symposium on Bioinformatics and Systems Biology, Kyoto, Japan. Best Poster Presentation.

Gusenleitner D, Auerbach R. Tice, S, Sherr DH, Monti S. 2013. Genomic signatures of carcinogenicity. Superfund Research Program Annual Meeting. Baton Rouge, Louisiana. Best Poster Presentation.

Novikov O, Parks A, Narasimhan S, Rolf S, Stanford E, Ubellacker J., **Sherr DH**. 2013. The role of environmental and endogenous ligands in tumor invasion and metastasis. Superfund Research Program Annual Meeting. Baton Rouge, Louisiana.

Novikov O, Parks A, Narasimhan S, Rolf S, Stanford E, Ubellacker J., **Sherr DH 2014** Regulation of AhR activation in triple negative breast cancer cells by tryptophan metabolites. America Physician Scientist Association, Chicago, Ill.

Stanford, EA, **Sherr DH**. 2014. The aryl hydrocarbon receptor controls breast cancer stem-like cell development and function. *The Toxicologist*. New England SOT Best Poster. SOT Annual Meeting, Phoenix, Az.

Sherr DH, Parks A, Monti S, Murphy GJ, Novikov O, Ubellacker J, Stanford E. 2014. The AHR controls breast cancer stem cell development and function. *The Toxicologist*. Symposium, SOT Annual Meeting, Phoenix, Az.

Bais, M, Stanford, EA, Novikov, O, **Sherr, DH**, Kukuruzinska, M, Trackman, P. 2014. Orthotopic Oral Cancer Mouse Model for Anti-oral Cancer Drug Screening. CTSI Symposium, Boston, MA.

Novikov, O, Stanford, EA, **Sherr DH**. 2014. The role of endogenous and environmental AhR ligands in mammary epithelial cell tumor growth and metastasis. CTSI Symposium, Boston, MA.

David Sherr, Ph.D.

Bais, M., Stanford EA, Novikov, O, **Sherr, DH**, Kukuruzinska, M., Trackman, P. 2014..Orthotopic Oral cancer mouse model to validate the anti-cancer activity of LOX-PP, tunicamycin and AHR modulators. American Assoc. of Dental Res. Annual Meeting, Boston, MA.

Novikov, O, Parks, Rolfe, S, Narasimhan, S, Stanford, EA, Ubellacker, J, **Sherr, DH**. 2014. The role of endogenous and environmental AhR ligands in mammary epithelial tumor growth and invasion. Superfund Research Program Annual Meeting, San Jose, CA.

Stanford, EA, Novikov, O, Wang, Z, Mulas, F, Monti, S, Murphy, GJ, **Sherr, DH**. 2015. The aryl hydrocarbon receptor controls breast cancer stem cell development and function. Society of Toxicology Annual Meeting, San Diego, CA.

Ash, P., Miurugi, J, Stanford, EA, Murphy, GJ, **Sherr, DH**, Wolozin, B. 2015. Environmental toxicant agonists of the aryl hydrocarbon receptor induce expression of TDP-43. Society of Neurology. Brain Research Meeting, Chicago, IL.

Stanford, EA, Kukuruzinska, MA, Bais, MV, and **Sherr, DH**. 2016. The role of the aryl hydrocarbon receptor and its diverse ligands in oral squamous cell carcinoma migration and tumorigenesis. Society of Toxicology Annual Meeting, New Orleans, LA.

Landesman-Bollag, E, Bitar, N, Sarita-Reyes, C, Lakloul, I, Stanford EA, Novikov, O, Wang, Z, Ramirez-Cardenas, A, **Sherr, DH**, Seldin DC. 2016.Pilot Study of AhR Signaling Components in Breast Cancer Tissue Microarray. Clinical and Translational Science Institute, Boston, MA.

Mohamed HT, Gadalla, R, El-Ghonaimy EA, Aziz Ibrahim SA, El-Shinawi M, Seldin DC, Sherr DH, and Mohamed MM. 2016. Over-expression of the aryl hydrocarbon receptor and cytochrome P450 1B1 correlates with poor prognostic factors in inflammatory breast cancer patients. San Antonio Breast Cancer Symposium, San Antonio, TX.

DeLisi CP, **Sherr DH**, Chen H-R, Hu Z. 2016. A computational method for repurposing approved drugs. Boston University Office of Technology Development annual showcase, Boston, MA.

Stanford EA, Ramirez-Cardenas A, Wang Z, Novikov O, Alamoud K, Kukuruzinska MA, Bais MV, Monti SM, and **Sherr DH**. 2016. AHR control of oral squamous cell carcinoma migration and tumorigenesis. 2016 International AHR conference, Rochester, NY

Narasimhan S, Stanford EA, Wang Z, Novikov O, Parks AJ, Mulas F, Monti S, and **Sherr DH** 2016. The contribution of the AHR to breast cancer cell migration and cancer stem cell production, and the puzzling effects of AHR agonists and antagonists. 2016 International AHR conference, Rochester, NY

David Sherr, Ph.D.

Novikov O, Wang Z , Stanford EA, Parks AH, Ramirez- Cardenas A, Landesman E, Laklouk I, Sarita-Reyes C, Gusenleitner D, Li A, Monti S, Manteiga S, Lee K and **Sherr DH**. 2016. An AHR-mediated positive feedback loop that enforces cell migration in triple negative human breast cancer cells. 2016 International AHR conference, Rochester, NY

GEROGE'S PEOPLE. 2016. Aryl hydrocarbon receptor (AHR) direction of definitive hematopoietic development. San Diego, CA